Thus, multiple drugs targeting the stress system have been tested for the treatment of depression, including corticosteroid synthesis inhibitors, GR antagonists, corticotrophin-releasing hormone receptor antagonists, tryptophan 2,3-dioxygenase inhibitors, and FK506-binding protein 51 (FKBP51) receptor antagonists [81]. This evidence concerns the gene NR3C1 and depressive disorder.